SCHEMBL2809708

SCHEMBL2809708

COc1ccccc1CNC(=O)c1ccc2c(c1)n(CCC(=O)O)c(=O)n2Cc1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 6/20 0.61
EPHX2 P34913 1/20 0.48
MAPT P10636 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
PKM P14618 1/20 0.48
CYP2C19 P33261 1/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
THRB P10828 2/20 0.47
TP53 P04637 3/20 0.47
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
CTSG P08311 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314153 0.92 CMA1 (0.59) CMA1MAPTTP53POLBCTSG
SCHEMBL2309651 0.86 TP53 (0.56) CMA1THRBTP53POLB
SCHEMBL2318188 0.85 CMA1 (0.71) CMA1TP53CTSG
SCHEMBL2312726 0.84 CMA1 (0.54) CMA1THRBTP53POLB
SCHEMBL2309320 0.84 CMA1 (0.67) CMA1CTSG
SCHEMBL2310106 0.83 CMA1 (0.63) CMA1HPGDCTSG
SCHEMBL2309308 0.80 CMA1 (0.61) CMA1CTSG
SCHEMBL2312014 0.79 CMA1 (0.67) CMA1CTSG
SCHEMBL2312025 0.78 CMA1 (0.58) CMA1CYP1A2PKMCYP2C19GAA
SCHEMBL2314295 0.78 CMA1 (0.63) CMA1CTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
EP-2152674-B1 BENZIMIDAZOLONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2011-08-03 EP disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2008147697-A1 BENZIMIDAZOLONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240702-A1 Benzimidazolone Chymase Inhibitors CMA1, SERPINB1, CPA3 CMA1 1/4885EPHX2 4039/4885MAPT 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.